Prostate cancer is one of the most common cancers affecting men worldwide. However, planning personalized radiotherapy in the advanced stages of the disease still requires more precise tools. Researchers at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) have now tested a novel approach. A combination of two diagnostic imaging techniques could pave the way for personalized radiotherapy. The results of the study, funded by the Wilhelm Sander Foundation, have been published in the Journal of Medicinal Chemistry (DOI: 10.1021/acs.jmedchem.6c00161).

A preclinical study led by the Josep Carreras Leukaemia Research Institute and the Centre for Genomics and Oncological Research at the University of Granada identifies a key mechanism underlying the progression of a subtype of childhood leukaemia and points to a potential new therapeutic strategy based on a drug already approved for other conditions.

Ulinastatin (UTI), a protein naturally found in human urine, exerts hepatoprotective effects by attenuating inflammation, oxidative stress, and cell death, and modulating immunity and hemostasis. This review synthesizes existing evidence on UTI's therapeutic potential across seven liver conditions, from sepsis-induced hepatic injury to liver cancer.